BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 2014;32:2399-405. [PMID: 24637174 DOI: 10.1016/j.vaccine.2014.02.096] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Burckhardt I, Sebastian K, Mauder N, Kostrzewa M, Burckhardt F, Zimmermann S. Analysis of Streptococcus pneumoniae using Fourier-transformed infrared spectroscopy allows prediction of capsular serotype. Eur J Clin Microbiol Infect Dis 2019;38:1883-90. [PMID: 31286288 DOI: 10.1007/s10096-019-03622-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Kurbatova EA, Akhmatova NK, Zaytsev AE, Akhmatova EA, Egorova NB, Yastrebova NE, Sukhova EV, Yashunsky DV, Tsvetkov YE, Nifantiev NE. Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related to Streptococcus pneumoniae Type 3 Capsular Polysaccharide. Front Immunol 2020;11:578019. [PMID: 33343566 DOI: 10.3389/fimmu.2020.578019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Hsiao HJ, Wu CT, Huang JL, Chiu CH, Huang YC, Lin JJ, Huang IA, Chan OW, Chou IJ, Hsia SH. Clinical features and outcomes of invasive pneumococcal disease in a pediatric intensive care unit. BMC Pediatr 2015;15:85. [PMID: 26184113 DOI: 10.1186/s12887-015-0387-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Caporuscio S, Ieraci R, Valesini G, Teloni R, Mariotti S, Spinelli FR, Ferlito C, Salemi S, Picchianti Diamanti A, Meneguzzi G, Markovic M, Sgrulletti M, von Hunolstein C, Ralli L, Pinto A, Salerno G, Canzoni M, Sorgi ML, Laganà B, Di Rosa R, Nisini R, D'Amelio R. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol 2018;195:18-27. [PMID: 30036638 DOI: 10.1016/j.clim.2018.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines 2021;20:243-56. [PMID: 33478306 DOI: 10.1080/14760584.2021.1880328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hughes GJ, Wright LB, Chapman KE, Wilson D, Gorton R. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect 2016;144:2654-69. [PMID: 27193457 DOI: 10.1017/S0950268816000856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
7 Parker AR, Skold M, Harding S, Barton JC, Bertoli LF, Barton JC. Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations. BMC Immunol 2019;20:29. [PMID: 31429700 DOI: 10.1186/s12865-019-0310-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Anderson R, Feldman C. Pneumolysin as a potential therapeutic target in severe pneumococcal disease. J Infect 2017;74:527-44. [PMID: 28322888 DOI: 10.1016/j.jinf.2017.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
9 Masters IB, Isles AF, Grimwood K. Necrotizing pneumonia: an emerging problem in children? Pneumonia (Nathan) 2017;9:11. [PMID: 28770121 DOI: 10.1186/s41479-017-0035-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 7.6] [Reference Citation Analysis]
10 Cui YA, Patel H, O'Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother 2017;13:1-13. [PMID: 28125317 DOI: 10.1080/21645515.2016.1277300] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
11 Li C, Duda KA, Elverdal PL, Skovsted IC, Kjeldsen C, Teze D, Duus JØ. Structural, biosynthetic and serological cross-reactive elucidation of capsular polysaccharides from Streptococcus pneumoniae serogroup 28. Carbohydr Polym 2021;254:117323. [PMID: 33357884 DOI: 10.1016/j.carbpol.2020.117323] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zivich PN, Grabenstein JD, Becker-Dreps SI, Weber DJ. Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review. Pneumonia (Nathan) 2018;10:11. [PMID: 30410854 DOI: 10.1186/s41479-018-0055-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
13 Yezli S, van der Linden M, Booy R, Alotaibi B. Pneumococcal disease during Hajj and Umrah: Research agenda for evidence-based vaccination policy for these events. Travel Medicine and Infectious Disease 2019;29:8-15. [DOI: 10.1016/j.tmaid.2018.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Bedos JP, Varon E, Porcher R, Asfar P, Le Tulzo Y, Megarbane B, Mathonnet A, Dugard A, Veinstein A, Ouchenir K, Siami S, Reignier J, Galbois A, Cousson J, Preau S, Baldesi O, Rigaud JP, Souweine B, Misset B, Jacobs F, Dewavrin F, Mira JP. Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study. Intensive Care Med 2018;44:2162-73. [PMID: 30456466 DOI: 10.1007/s00134-018-5444-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Briles DE, Paton JC, Mukerji R, Swiatlo E, Crain MJ. Pneumococcal Vaccines. Microbiol Spectr 2019;7. [PMID: 31858954 DOI: 10.1128/microbiolspec.GPP3-0028-2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
16 Morales M, Martín-Galiano AJ, Domenech M, García E. Insights into the Evolutionary Relationships of LytA Autolysin and Ply Pneumolysin-Like Genes in Streptococcus pneumoniae and Related Streptococci. Genome Biol Evol 2015;7:2747-61. [PMID: 26349755 DOI: 10.1093/gbe/evv178] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
17 Elberse KE, Wagenvoort GH, Pluister GN, de Melker HE, Sanders EA, van der Ende A, Knol MJ. Pneumococcal population in the era of vaccination: changes in composition and the relation to clinical outcomes. Future Microbiol 2016;11:31-41. [PMID: 26673757 DOI: 10.2217/fmb.15.119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Palacios PA, Duarte C, Sanabria O, Moreno J. Molecular characterization of non-vaccine Streptococcus pneumoniae serotypes 11A, 15 B/C and 23A recovered from invasive isolates in Colombia. biomedica 2017;37:390. [DOI: 10.7705/biomedica.v37i3.3223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Sugimoto N, Yamagishi Y, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, Koizumi Y, Mikamo H. Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review. BMC Res Notes 2017;10:21. [PMID: 28057059 DOI: 10.1186/s13104-016-2353-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
20 Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 2021:S0264-410X(21)01097-5. [PMID: 34507861 DOI: 10.1016/j.vaccine.2021.08.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wagner-Muñiz DA, Haughney SL, Kelly SM, Wannemuehler MJ, Narasimhan B. Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity. Front Immunol 2018;9:325. [PMID: 29599766 DOI: 10.3389/fimmu.2018.00325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
22 Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH. Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev 2015;28:871-99. [PMID: 26085553 DOI: 10.1128/CMR.00024-15] [Cited by in Crossref: 348] [Cited by in F6Publishing: 192] [Article Influence: 49.7] [Reference Citation Analysis]
23 Polkowska A, Skoczyńska A, Paradowska-Stankiewicz I, Stefanoff P, Hryniewicz W, Kuch A, Lyytikäinen O, Nuorti JP. Pneumococcal meningitis before the introduction of 10-valent pneumococcal conjugate vaccine into the National Childhood Immunization Program in Poland. Vaccine 2019;37:1365-73. [PMID: 30638798 DOI: 10.1016/j.vaccine.2018.12.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Furuya Y, Yamagishi Y, Okade H, Kadota T, Funatsu T, Eto M, Nomura N, Mitsuyama J, Mikamo H. Impact of the pneumococcal conjugate vaccine on serotype distribution of adult non-invasive Streptococcus pneumoniae isolates in Tokai region, Japan, 2008-2016. J Infect Chemother 2017;23:394-9. [PMID: 28427991 DOI: 10.1016/j.jiac.2017.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Wiese AD, Griffin MR, Zhu Y, Mitchel EF Jr, Grijalva CG. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era. Vaccine 2016;34:6243-9. [PMID: 27832918 DOI: 10.1016/j.vaccine.2016.10.062] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
26 Müller A, Schramm DB, Kleynhans J, de Gouveia L, Meiring S, Ramette A, von Gottberg A, Hathaway LJ. Cytokine response in cerebrospinal fluid of meningitis patients and outcome associated with pneumococcal serotype. Sci Rep 2021;11:19920. [PMID: 34620928 DOI: 10.1038/s41598-021-99190-3] [Reference Citation Analysis]
27 Müller A, Kleynhans J, de Gouveia L, Meiring S, Cohen C, Hathaway LJ, von Gottberg A; for GERMS-SA. Streptococcus pneumoniae Serotypes Associated with Death, South Africa, 2012-2018. Emerg Infect Dis 2022;28:166-79. [PMID: 34932448 DOI: 10.3201/eid2801.210956] [Reference Citation Analysis]
28 Müller A, Salmen A, Aebi S, de Gouveia L, von Gottberg A, Hathaway LJ. Pneumococcal serotype determines growth and capsule size in human cerebrospinal fluid. BMC Microbiol 2020;20:16. [PMID: 31959125 DOI: 10.1186/s12866-020-1700-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Forstner C, Kolditz M, Kesselmeier M, Ewig S, Rohde G, Barten-Neiner G, Rupp J, Witzenrath M, Welte T, Pletz MW; CAPNETZ study group. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia. Vaccine 2020;38:1129-36. [PMID: 31761500 DOI: 10.1016/j.vaccine.2019.11.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
30 Ciprero KL, Marchese RD, Richard P, Baudin M, Sterling TM, Manoff SB, Radley D, Stek JE, Soubeyrand B, Grabenstein JD, Samson SI, Musey LK. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. Hum Vaccin Immunother 2016;12:2135-41. [PMID: 27002793 DOI: 10.1080/21645515.2016.1156270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Corcoran JP, Wrightson JM, Belcher E, DeCamp MM, Feller-Kopman D, Rahman NM. Pleural infection: past, present, and future directions. Lancet Respir Med 2015;3:563-77. [PMID: 26170076 DOI: 10.1016/S2213-2600(15)00185-X] [Cited by in Crossref: 47] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
32 De Miguel S, Latasa P, Yuste J, García L, Ordobás M, Ramos B, Pérez M, Ortiz MA, Sanz JC. Age-Dependent Serotype-Associated Case-Fatality Rate in Invasive Pneumococcal Disease in the Autonomous Community of Madrid between 2007 and 2020. Microorganisms 2021;9:2286. [PMID: 34835413 DOI: 10.3390/microorganisms9112286] [Reference Citation Analysis]
33 Cillóniz C, Amaro R, Torres A. Pneumococcal vaccination. Curr Opin Infect Dis 2016;29:187-96. [PMID: 26779776 DOI: 10.1097/QCO.0000000000000246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
34 Babb R, Doyle CR, Pirofski LA. Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3. Microbiol Spectr 2021;:e0144621. [PMID: 34756090 DOI: 10.1128/Spectrum.01446-21] [Reference Citation Analysis]
35 Alnimr AM, Farhat M. Phenotypic and molecular study of pneumococci causing respiratory tract infections. A 3-year prospective cohort. Saudi Med J 2017;38:350-8. [PMID: 28397940 DOI: 10.15537/smj.2017.4.17976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Prebil K, Beović B, Paragi M, Seme K, Kastrin T, Plesničar BK, Petek B, Martinčič Ž. First report of an outbreak of pneumonia caused by Streptococcus pneumoniae serotype 6A. Wien Klin Wochenschr 2016;128:68-70. [PMID: 26466838 DOI: 10.1007/s00508-015-0864-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Harding CM, Nasr MA, Scott NE, Goyette-Desjardins G, Nothaft H, Mayer AE, Chavez SM, Huynh JP, Kinsella RL, Szymanski CM, Stallings CL, Segura M, Feldman MF. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host. Nat Commun 2019;10:891. [PMID: 30792408 DOI: 10.1038/s41467-019-08869-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
38 Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, Nilsson JÅ, Truedsson L, Kapetanovic MC. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther 2015;17:124. [PMID: 25986458 DOI: 10.1186/s13075-015-0636-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
39 Fontana NS, Ibrahim KY, Bonazzi PR, Rossi F, Almeida SCG, Tengan FM, Brandileone MCC, Abdala E. Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients. Sci Rep 2021;11:3699. [PMID: 33580101 DOI: 10.1038/s41598-021-81415-0] [Reference Citation Analysis]
40 Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N. Theory and strategy for Pneumococcal vaccines in the elderly. Hum Vaccin Immunother 2016;12:336-43. [PMID: 26406267 DOI: 10.1080/21645515.2015.1075678] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
41 Xu Y, Wang Q, Yao K, Dong F, Song W, Liu G, Xu B, Shi W, Li Y, Li K, Liu Y, Qian S. Clinical characteristics and serotype distribution of invasive pneumococcal disease in pediatric patients from Beijing, China. Eur J Clin Microbiol Infect Dis 2021;40:1833-42. [PMID: 33786728 DOI: 10.1007/s10096-021-04238-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Luck JN, Tettelin H, Orihuela CJ. Sugar-Coated Killer: Serotype 3 Pneumococcal Disease. Front Cell Infect Microbiol 2020;10:613287. [PMID: 33425786 DOI: 10.3389/fcimb.2020.613287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
43 Shigayeva A, Rudnick W, Green K, Tyrrell G, Demczuk WH, Gold WL, Gubbay J, Jamieson F, Plevneshi A, Pong-Porter S, Richardson S, McGeer A; Toronto Invasive Bacterial Diseases Network. Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003-2011. Vaccine 2016;34:846-53. [PMID: 26602266 DOI: 10.1016/j.vaccine.2015.11.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
44 Danis K, Varon E, Lepoutre A, Janssen C, Forestier E, Epaulard O, N'guyen Y, Labrunie A, Lanotte P, Gravet A, Pelloux I, Chavanet P, Levy-Bruhl D, Ploy MC, Gaillat J; SIIPA Group . Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France. Open Forum Infect Dis 2019;6:ofz510. [PMID: 31868865 DOI: 10.1093/ofid/ofz510] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
45 Alarcón ZK, Duarte C, Sanabria O, Moreno J. Streptococcus pneumoniae serotype 3 genotypes in invasive isolates from Colombia. Biomedica 2021;41:338-46. [PMID: 34214273 DOI: 10.7705/biomedica.5407] [Reference Citation Analysis]
46 Macintyre AN, French MJ, Sanders BR, Riebe KJ, Shterev ID, Wiehe K, Hora B, Evangelous T, Dugan G, Bourland JD, Cline JM, Sempowski GD. Long-Term Recovery of the Adaptive Immune System in Rhesus Macaques After Total Body Irradiation. Adv Radiat Oncol 2021;6:100677. [PMID: 34646962 DOI: 10.1016/j.adro.2021.100677] [Reference Citation Analysis]
47 Deb A, Guggisberg P, Mutschler T, Owusu-Edusei K, Bencina G, Johnson KD, Ignacio T, Mathijssen D, Qendri V. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Rev Vaccines 2022. [PMID: 35220875 DOI: 10.1080/14760584.2022.2046468] [Reference Citation Analysis]
48 Sanz-Herrero F, Gimeno-Cardona C, Tormo-Palop N, Fernández-Fabrellas E, Briones ML, Cervera-Juan Á, Blanquer-Olivas J. The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia. Vaccine 2016;34:1847-52. [PMID: 26845737 DOI: 10.1016/j.vaccine.2016.01.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
49 Houseman C, Chapman KE, Manley P, Gorton R, Wilson D, Hughes GJ. Decreasing case fatality rate following invasive pneumococcal disease, North East England, 2006-2016. Epidemiol Infect 2019;147:e175. [PMID: 31063115 DOI: 10.1017/S0950268819000657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
50 Wiese AD, Griffin MR, Grijalva CG. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines 2019;18:327-41. [PMID: 30759352 DOI: 10.1080/14760584.2019.1582337] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
51 Li C, Duda KA, Elverdal PL, Skovsted IC, Kjeldsen C, Duus JØ. Structural, Biosynthetic, and Serological Cross-Reactive Elucidation of Capsular Polysaccharides from Streptococcus pneumoniae Serogroup 16. J Bacteriol 2019;201:e00453-19. [PMID: 31383737 DOI: 10.1128/JB.00453-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
52 Takeda H, Sato C, Bin C, Nishidzuka M, Watanabe M, Yamamoto T, Suzuki H, Oishi K, Tsuchida F. Changes in the Pneumococcal Vaccine Serotypes in Adult Noninvasive Pneumonia after the Introduction of Pneumococcal Conjugate Vaccination for Children. J Glob Infect Dis 2019;11:30-5. [PMID: 30814833 DOI: 10.4103/jgid.jgid_167_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Wagenvoort GH, Sanders EA, Vlaminckx BJ, Elberse KE, de Melker HE, van der Ende A, Knol MJ. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands. Vaccine 2016;34:1077-85. [PMID: 26778420 DOI: 10.1016/j.vaccine.2015.12.066] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]